UA106506C2 - Інсулінвмісний фармацевтичний препарат для перорального застосування - Google Patents

Інсулінвмісний фармацевтичний препарат для перорального застосування

Info

Publication number
UA106506C2
UA106506C2 UAA201202346A UAA201202346A UA106506C2 UA 106506 C2 UA106506 C2 UA 106506C2 UA A201202346 A UAA201202346 A UA A201202346A UA A201202346 A UAA201202346 A UA A201202346A UA 106506 C2 UA106506 C2 UA 106506C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical preparation
insulin
oral administration
containing pharmaceutical
preparation intended
Prior art date
Application number
UAA201202346A
Other languages
English (en)
Russian (ru)
Inventor
Др. Зольтан СИЛЬВАШШИ
Original Assignee
Цера-Мед Кфт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цера-Мед Кфт. filed Critical Цера-Мед Кфт.
Publication of UA106506C2 publication Critical patent/UA106506C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід належить до фармацевтичного препарату для перорального застосування, що містить комбінацію одержаного біотехнологічними методами людського рекомбінантного інсуліну та/або модифікованого інсуліну, або аналога та/або його похідного, інгібітору протеази і високомолекулярного (природного) білка. Винахід також належить до способу виготовлення згаданого фармацевтичного препарату і його застосування в лікуванні цукрового діабету у ссавців.
UAA201202346A 2009-08-03 2010-08-02 Інсулінвмісний фармацевтичний препарат для перорального застосування UA106506C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
UA106506C2 true UA106506C2 (uk) 2014-09-10

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202346A UA106506C2 (uk) 2009-08-03 2010-08-02 Інсулінвмісний фармацевтичний препарат для перорального застосування

Country Status (15)

Country Link
US (1) US20120129769A1 (uk)
EP (1) EP2461820A1 (uk)
JP (1) JP2013501043A (uk)
KR (1) KR20120088660A (uk)
CN (1) CN102791282A (uk)
AU (1) AU2010280418B2 (uk)
BR (1) BR112012002413A2 (uk)
CA (1) CA2769620A1 (uk)
HU (1) HUP0900482A2 (uk)
IL (1) IL217856A0 (uk)
MX (1) MX2012001461A (uk)
RU (1) RU2012109006A (uk)
UA (1) UA106506C2 (uk)
WO (1) WO2011015984A1 (uk)
ZA (1) ZA201201519B (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2726091T3 (pl) * 2011-06-29 2020-08-10 Rani Therapeutics, Llc Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
US20200126671A1 (en) * 2017-06-28 2020-04-23 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for determining the risk to develop type 1 diabetes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
CA2125284C (en) 1991-12-05 2000-06-20 Jens-Christian Wunderlich Peroral administration form for peptidic medicaments, in particular insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5968899A (en) * 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
NZ500075A (en) 1997-04-02 2001-03-30 Purdue Research Foundation Method for the oral delivery of a protein encapsulated within a hydrogel matrix
CN1329502A (zh) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 含有胰岛素的药物组合物
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
PT1454630E (pt) 2003-03-04 2010-12-15 Technology Dev Company Ltd Composição de insulina injectável de acção prolongada e métodos para o seu fabrico e utilização
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
EP2722054B1 (en) * 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
EP2164466A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment

Also Published As

Publication number Publication date
KR20120088660A (ko) 2012-08-08
AU2010280418A1 (en) 2012-03-22
RU2012109006A (ru) 2013-09-10
AU2010280418B2 (en) 2015-04-09
EP2461820A1 (en) 2012-06-13
JP2013501043A (ja) 2013-01-10
ZA201201519B (en) 2013-05-29
MX2012001461A (es) 2012-05-22
HUP0900482A2 (en) 2011-03-28
IL217856A0 (en) 2012-03-29
US20120129769A1 (en) 2012-05-24
WO2011015984A1 (en) 2011-02-10
CA2769620A1 (en) 2011-02-10
BR112012002413A2 (pt) 2016-03-01
CN102791282A (zh) 2012-11-21
HU0900482D0 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PH12016500004A1 (en) Pcsk9 vaccine
MY167234A (en) Novel glucagon analogues
NZ602541A (en) Long - acting formulations of insulins
NZ703153A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
NZ595063A (en) Polypeptides from neisseria meningitidis
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
WO2011080102A3 (en) Glp-1 analogues and derivatives
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2012007159A3 (en) Novel gastro-retentive dosage forms
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
GB2501219A (en) Orally bioavailable peptide drug compositions and methods thereof
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
WO2013010048A3 (en) Non-standard insulin analogues
MX2013003523A (es) Composicion farmaceutica de dosis baja.
UA106506C2 (uk) Інсулінвмісний фармацевтичний препарат для перорального застосування
WO2011065867A3 (en) Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
WO2012062873A3 (en) Highly immunogenic hiv p24 sequences
IN2014DN09383A (uk)
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.